Search Results

SPR® Therapeutics, a leader in the use of peripheral nerve stimulation (PNS) to address different types of pain throughout the body, announced the publication of a review of prospective studies evaluating the impact on chronic pain following percutaneous PNS treatment.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Neuros Medical, Inc. announced acceptance for publication of the 3-month results from the landmark QUEST Study demonstrating treatment with the Altius® Direct Electrical Nerve Stimulation System results in immediate and lasting pain reduction, decreased opioid use, and improved quality of life in patients suffering with chronic post-amputation pain.

SPR Therapeutics announced the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”) today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research on the nature, mechanisms and treatment of pain.

Nalu Medical Inc. revealed significant findings from a landmark clinical trial evaluating the Nalu Peripheral Nerve Stimulation System utilizing their proprietary micro-implantable pulse generator to treat chronic pain patients.

RespireRx Pharmaceuticals Inc. is pleased to announce that KRM-II-81, its lead GABA A receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative ® Preclinical Screening Platform for Pain.

Nearly one out of four Americans (23.3%) suffer from chronic low back pain. A new study finds that low-intensity continuous ultrasound, such as ZetrOZ Systems’ sustained acoustic medicine (sam®) technology, alleviates the symptoms of chronic lower back pain and reduces the need for pain medication.

Artelo Biosciences, Inc. today announced that Professor Saoirse O’Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society.